TrialNature medicine2025

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Neal D Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.